Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Neoplasms × Etoposide × Clear all

Phase

Status

Completed 12 Terminated 3 Active not recruiting 3 Withdrawn 1 Suspended 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 9 Lymphoma 7 Small Cell Lung Carcinoma 5 Lymphoma, Non-Hodgkin 4 Lung Neoplasms 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Lymphoma, Large-Cell, Immunoblastic 3 Lymphoma, Follicular 3 Hodgkin Disease 3 Carcinoma, Non-Small-Cell Lung 3 Burkitt Lymphoma 3 Waldenstrom Macroglobulinemia 2 Sarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Lymphoma, Mantle-Cell 2 Lymphoma, Large-Cell, Anaplastic 2 Lymphoma, B-Cell, Marginal Zone 2 Lymphoma, AIDS-Related 2 Leukemia, Myeloid, Acute 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Dendritic Cell Sarcoma, Interdigitating 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Testicular Neoplasms 1 Testicular Germ Cell Tumor 1 Sezary Syndrome 1 Rhabdoid Tumor 1 Retinoblastoma 1 Recurrence 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Neuroectodermal Tumors, Primitive 1

Interventions

Cisplatin 9 pembrolizumab 5 Radiosurgery 5 Gemcitabine 5 Taxes 4 Paclitaxel 4 Dexamethasone 4 trametinib 3 ibrutinib 3 Surveys and Questionnaires 3 Standard of Care 3 Radiotherapy 3 Nivolumab 3 Magnetic Resonance Spectroscopy 3 Fluorouracil 3 Carboplatin 3 Ascorbic Acid 3 tocilizumab 2 pazopanib 2 obinutuzumab 2 naquotinib 2 lenvatinib 2 fludarabine 2 enzalutamide 2 Trastuzumab 2 Surgical Procedures, Operative 2 SS1(dsFv)PE38 2 Radiation Dose Hypofractionation 2 Pemetrexed 2 Ondansetron 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02947113 2017-11-30

HYPOLAN

The Netherlands Cancer Institute

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡